nach oben

Quality of Life Research

Erschienen in:

01.08.2007 | Original Paper

Predicting quality of life impairment in chronic schizophrenia from cognitive variables

verfasst von: Michael S. Ritsner

Erschienen in: Quality of Life Research | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Background The aim of this study was to see whether and how cognition deficit predicts quality of life impairments in schizophrenia patients. Method The Computerized Cambridge Automated Neuropsychological Test Battery, the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and the Quality of Life Scale (QLS) were used to assess 62 patients with chronic schizophrenia. Step-wise multiple regression analysis was used in order to determine cognitive variables that would predict the scores of each Q-LES-Q and QLS domain scores. Results Regression analysis revealed a significant association of the cognitive deficits with both general and domain-specific quality of life impairment measured with Q-LES-Q and QLS. Deficits in executive functions, visual sustained attention, memory and motor skills have been found to be valid predictors both before and after controlling for the severity of symptoms, emotional distress, side effects, age, education, and illness duration. Conclusions This study suggests that deficits in executive functioning, attention, memory and motor skills substantially contributes to predicting impairments across a wide range of HRQL domains, and, consequently, to quality of life appraisal in schizophrenia. Cognitive predictors cannot be attributed to illness-related and background variables. It can be concluded that, when aiming at the improvement of quality of life in schizophrenia patients, cognitive functioning should be targeted.

Testa, M. A., & Simonson, D. C. (1996). Assessment of quality-of-life outcomes. The New England Journal of Medicine, 334, 835–840.PubMedCrossRef

Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, 273, 59–65.PubMedCrossRef

Ritsner, M. S. (2007). The distress/protection vulnerability model of the quality of life impairment syndrome: Current evidence and new directions for research. In M. S. Ritsner & A. G. Awad (Eds.), Quality of life impairment in Schizophrenia, mood and anxiety disorders. New perspectives on research and treatment (pp. 3–19). Springer.

Keefe, R. S., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., Adler, L. W., Manschreck, T. C., Swartz, M., Rosenheck, R., Perkins, D. O., Walker, T. M., Stroup, T. S., McEvoy, J. P., & Lieberman, J. A. (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31, 2033–2046.PubMedCrossRef

Heslegrave, R. J., Awad, A. G., & Voruganti, L. N. (1997). The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. Journal of Psychiatry and Neuroscience, 22, 235–243.PubMed

Addington, J., & Addington, D. (2002). Cognitive functioning in first-episode schizophrenia. Journal of Psychiatry and Neuroscience, 27, 188–192.PubMed

Kaiser, W. (2000). Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life. British Journal of Psychiatry, 176, 92–93.PubMedCrossRef

Aksaray, G., Oflu, S., Kaptanoglu, C., & Bal, C. (2002). Neurocognitive deficits and quality of life in outpatients with schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry, 26, 1217–1219.CrossRef

Sota, T. L., & Heinrichs, R. W. (2004). Demographic, clinical, and neurocognitive predictors of quality of life in schizophrenia patients receiving conventional neuroleptics. Comprehensive Psychiatry, 45, 415–421.PubMedCrossRef

10.

Alptekin, K., Akvardar, Y., Kivircik Akdede, B. B., et al. (2005). Is quality of life associated with cognitive impairment in schizophrenia?. Progress in Neuro-psychopharmacology and Biological Psychiatry, 29, 239–244.PubMedCrossRef

11.

Wegener, S., Redoblado-Hodge, M. A., Lucas, S., et al. (2005). Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. The Australian and New Zealand Journal of Psychiatry, 39, 487–492.PubMedCrossRef

12.

Awad, A. G., Voruganti, L. N., & Heslegrave, R. J. A. (1997). Conceptual model of quality of life in schizophrenia: Description and preliminary drugs, relationships to objective psychopathology, quality of life, clinical validation. Quality of Life Research, 6, 21–26.PubMedCrossRef

13.

Ritsner, M., Modai, I., Endicott, J., Rivkin, O., Nechamkin, Y., Barak, P., Goldin, V., & Ponizovsky, A. (2000). Differences in quality of life domains, psychopathological and psychosocial factors in psychiatric patients. Journal of Clinical Psychiatry, 61, 880–889.PubMedCrossRef

14.

Ritsner, M., Gibel, A., & Ratner, Y. (2006). Determinants of changes in perceived quality of life in the course of Schizophrenia. Quality of Life Research, 15, 515–526.PubMedCrossRef

15.

Fitzgerald, P. B., Williams, C. L., Corteling, N., et al. (2001). Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica, 103, 387–392 .PubMedCrossRef

16.

Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984). The Quality of Life Scale: An instrument for rating the schizophrenic deficit scale. Schizophrenia Bulletin, 10, 388–398.PubMed

17.

American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders. Washington, DC.

18.

Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacology Bulletin, 29, 321–326.PubMed

19.

Ritsner, M., Modai, I., Kurs, R., et al. (2002). Subjective quality of life measurements in severe mental health patients: Measuring quality of life of psychiatric patients: Comparison two questionnaires. Quality Life Research, 11, 553–561.CrossRef

20.

Sahakian, B. J., & Owen, A. M. (1992). Computerized assessment in neuropsychiatry using CANTAB: Discussion paper. Journal of the Royal Society of Medicine, 85, 399–402.PubMed

21.

Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes, L., & Rabbitt, P. (1994). Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. Dementia, 5, 266–281.PubMedCrossRef

22.

Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.PubMed

23.

Ritsner, M., Rabinowitz, J., & Slyuzberg, M. (1995). The Talbieh Brief Distress Inventory: A brief instrument to measure psychological distress among immigrants. Comprehensive Psychiatry, 36, 448–453.PubMedCrossRef

24.

Chouinard, G., Ross-Chouinard, A., Annale, L., et al. (1980). Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences, 7, 233.

25.

White, L., Harvey, P. D., Opler, L., Lindenmayer, J. P. & PANSS Study Group. (1997). Empirical assessment of the factorial structure of clinical symptoms in Schizophrenia. Psychopathology, 30, 263–274.

26.

Ritsner, M., Modai, I., & Ponizovsky, A. (2002). The Talbieh brief distress inventory: Validation for use with psychiatric patients. Comprehensive Psychiatry, 2, 144–163.

27.

Hintze, J. L., NCSS & PASS. (2001). Statistical system for Windows. User’s guide. number cruncher statistical systems, number cruncher statistical systems, Kaysville. Utah. www.NCSS.com.

28.

Awad, A. G., & Voruganti, L. N. (2004). Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs, 18, 877–893.PubMedCrossRef

29.

Lambert, M., & Naber, D. (2004). Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life. CNS Drugs, 2 (18 Suppl), 5–17.CrossRef

30.

Ritsner, M., & Kurs, R. (2006). Quality-of-life impairment in severe mental illness: Focus on Schizoaffective disorders. In William H. Murray (ed.), Schizoaffective disorder: New research. (pp. 69–107). NY: NOVA Publishers.

31.

Erlenmeyer-Kimling, L., Rock, D., Roberts, S. A., Janal, M., Kestenbaum, C., Cornblatt, B., & Adamo, U. H. (2000). Gottesman II. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: The New York High-Risk Project. The American Journal of Psychiatry, 157, 1416–1422.PubMedCrossRef

32.

Zalla, T., Joyce, C., Szoke, A., Schurhoff, F., Pillon, B., Komano, O., Perez-Diaz, F., Bellivier, F., Alter, C., Dubois, B., Rouillon, F., Houde, O'., & Leboyer, M. (2004). Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Research, 21, 207–217.CrossRef

33.

Hoff, A. L., Svetina, C., Maurizio, A. M., Crow, T. J., Spokes, K., & DeLisi, L. E. (2005). Familial cognitive deficits in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 133, 43–49.CrossRef

34.

Saperstein, A. M., Fuller, R. L., Avila, M. T., Adami, H., McMahon, R. P., Thaker, G. K., & Gold, J. M. (2006). Spatial working memory as a cognitive endophenotype of schizophrenia: Assessing risk for pathophysiological dysfunction. Schizophrenia Bulletin, 32, 498–506.PubMedCrossRef

35.

Chen, W. J., & Faraone, S. V. (2000). Sustained attention deficits as markers of genetic susceptibility to schizophrenia. American Journal of Medical Genetics, 97, 52–57.PubMedCrossRef

36.

Liu, S. K., Chiu, C. H., Chang, C. J., Hwang, T. J., Hwu, H. G., & Chen, W. J. (2002). Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. The American Journal of Psychiatry, 159, 975–982.PubMedCrossRef

37.

Bozikas, V. P., Andreou, C., Giannakou, M., Tonia, T., Anezoulaki, D., Karavatos, A., Fokas, K., & Kosmidis, M. H. (2005). Deficits in sustained attention in schizophrenia but not in bipolar disorder. Schizophrenia Research, 78, 225–233.PubMedCrossRef

38.

Stone, W. S., Faraone, S. V., Seidman, L. J., et al. (2001). Concurrent validation of schizotaxia: A pilot study. Biological Psychiatry, 50, 434–440.PubMedCrossRef

39.

Tsuang, M. T., Stone, W. S., Gamma, F., & Faraone, S. V. (2003). Schizotaxia: Current status and future directions. Current Psychiatry Reports, 5, 128–134.PubMedCrossRef

40.

Erickson, D. H., Beiser, M., Iacono, W. G., et al. (1989). The role of social relationships in the course of first-episode schizophrenia and affective psychosis. The American Journal of Psychiatry, 146, 1456–1461.PubMed

41.

Bechdolf, A., Pukrop, R., Kohn, D., et al. (2005). Subjective quality of life in subjects at risk for a first episode of psychosis: A comparison with first episode schizophrenia patients and healthy controls. Schizophrenia Research, 79, 137–143.PubMedCrossRef

Titel: Predicting quality of life impairment in chronic schizophrenia from cognitive variables
verfasst von: Michael S. Ritsner
Publikationsdatum: 01.08.2007
Verlag: Springer Netherlands
Erschienen in: Quality of Life Research / Ausgabe 6/2007
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-007-9195-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Health related quality of life in different states of breast cancer

Factors associated with health-related quality of life among hemodialysis patients in the DOPPS

Responsiveness to change to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer

Rod O’Connor: Measuring quality of life in health

Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis

Life satisfaction decreases during adolescence